Wigen Biomedicine Technology (Shanghai) Co. Ltd. has described pyrrolopyrimidine derivatives as Wee1-like protein kinase (Wee-1) inhibitors reported to be useful for the treatment of cancer.
Immunocytokines (ICs) engage multiple mechanisms of action by the use of antibodies to deliver cytokine payloads to the surface of the same immune cell, known as cis-signaling. Researchers from Bright Peak Therapeutics AG have developed ICs by using a novel approach based on site-specific chemical conjugation of engineered cytokines to existing nonmodified antibodies.
Astellas Pharma Inc.’s zolbetuximab, a monoclonal antibody targeting Claudin 18.2, met the primary endpoint of progression-free survival in the phase III Spotlight trial in CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, according to top-line data.
Genfleet Therapeutics (Shanghai) Inc. has divulged pyridino- or pyrimido-cyclic compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
An AU$300,000 grant from The Australian Pancreatic Cancer Foundation (Pankind) will support research at the Garvan Institute of Medical Research into the use of a porcupine-targeting molecule for pancreatic cancer.
Astellas Pharma Inc.’s zolbetuximab, a monoclonal antibody targeting Claudin 18.2, met the primary endpoint of progression-free survival in the phase III Spotlight trial in CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, according to top-line data.
Sunshine Biopharma Inc. has entered into a collaboration agreement with a leading lipid nanoparticle (LNP) formulation company to advance the development of Sunshine's mRNA-based anticancer macromolecule, K1.1.
Circulating tumor cells (CTCs) transit through the bloodstream and they exhibit heterogeneity in their expression of epithelial and mesenchymal marker proteins, including the cadherin proteins. Based on these findings, researchers from Massachusetts General Hospital and Harvard Medical School evaluated the potential of the dual anti-cadherin antibody, 23C6, in targeting CTC-dependent blood-borne metastasis.
